Pfizer Inc. (NYSE:PFE) Stock Holdings Lifted by FSM Wealth Advisors LLC

FSM Wealth Advisors LLC increased its stake in Pfizer Inc. (NYSE:PFE – Free Report) by 7.4% during the first quarter, HoldingsChannel.com reports. The fund owned 18,597 shares of the biopharmaceutical company’s stock after buying an additional 1,277 shares during the period. FSM Wealth Advisors LLC’s holdings in Pfizer were worth $759,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Moneta Group Investment Advisors LLC boosted its stake in Pfizer by 89,592.7% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock worth $8,257,000,000 after purchasing an additional 160,963,976 shares during the period. Norges Bank purchased a new position in shares of Pfizer during the fourth quarter valued at $3,150,472,000. Morgan Stanley lifted its position in shares of Pfizer by 10.3% in the fourth quarter. Morgan Stanley now owns 79,499,361 shares of the biopharmaceutical company’s stock worth $4,073,547,000 after purchasing an additional 7,419,929 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Pfizer by 13.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 59,828,849 shares of the biopharmaceutical company’s stock worth $3,097,341,000 after purchasing an additional 6,972,650 shares during the period. Finally, Renaissance Technologies LLC purchased a new position in Pfizer during the first quarter valued at approximately $311,238,000. 67.80% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

PFE has been the subject of a number of research reports. Barclays decreased their target price on shares of Pfizer from $43.00 to $40.00 in a research note on Wednesday, May 3rd. Morgan Stanley lowered their target price on Pfizer from $45.00 to $44.00 and set an “equal weight” rating on the stock in a research note on Monday, April 10th. UBS Group cut their price target on Pfizer from $41.00 to $39.00 in a research note on Friday, May 5th. StockNews.com cut Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, June 30th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Pfizer in a research note on Wednesday, May 17th. Eleven equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $46.67.

Insiders Place Their Bets

Want More Great Investing Ideas?

In related news, Director Scott Gottlieb bought 1,000 shares of Pfizer stock in a transaction that occurred on Monday, May 8th. The stock was acquired at an average price of $38.58 per share, for a total transaction of $38,580.00. Following the completion of the purchase, the director now owns 6,000 shares in the company, valued at $231,480. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.05% of the company’s stock.

Pfizer Stock Down 0.3 %

PFE stock opened at $35.53 on Monday. The stock has a market capitalization of $200.58 billion, a price-to-earnings ratio of 6.99, a price-to-earnings-growth ratio of 1.18 and a beta of 0.61. The company has a 50-day moving average of $38.03 and a two-hundred day moving average of $41.50. Pfizer Inc. has a 52-week low of $35.35 and a 52-week high of $54.93. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.37 and a quick ratio of 1.11.

Pfizer (NYSE:PFE – Free Report) last announced its earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $1.23 earnings per share for the quarter, beating the consensus estimate of $1.00 by $0.23. Pfizer had a return on equity of 37.53% and a net margin of 31.25%. The firm had revenue of $18.28 billion during the quarter, compared to the consensus estimate of $16.49 billion. During the same quarter in the prior year, the company earned $1.62 EPS. The firm’s revenue for the quarter was down 28.8% compared to the same quarter last year. As a group, equities research analysts anticipate that Pfizer Inc. will post 3.35 EPS for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 5th. Shareholders of record on Friday, July 28th will be issued a $0.41 dividend. This represents a $1.64 dividend on an annualized basis and a yield of 4.62%. The ex-dividend date of this dividend is Thursday, July 27th. Pfizer’s dividend payout ratio (DPR) is presently 32.28%.

About Pfizer

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women’s health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.